Advanced Physician Search: Rectal

The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.

Drug: NG-350A IV administration, Drug: Capecitabine oral administration, Radiation: Radiotherapy

The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor.

Radiation: Short-course radiation therapy, Drug: CAPOX chemotherapy, Drug: FOLFOX chemotherapy